TheraVet: growing interest in canine osteosarcoma
Since the project was launched at the end of 2022, the number of participating centers has risen by 300% to 16 in seven countries, says the veterinary biotechnology company.
Since its official launch two months ago, this number has increased by 33%, adds TheraVet.
Its osteosarcoma program consists of a minimally invasive limb-sparing solution that could provide an alternative to amputation in dogs.
This component can also be combined with all the non-surgical management options already available, such as chemotherapy or radiotherapy.
With around 40.000 cases per year in Europe and the United States, osteosarcoma is a serious disease with a poor prognosis, severely affecting dogs' quality of life through severe pain and reduced mobility.
Following this announcement, TheraVet's share price rose by 0.5% on Thursday, after having gained up to 10% in early morning trading.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction